VA
VKTX icon

Vident Advisory’s Viking Therapeutics VKTX Stock Holding History

Vident Advisory’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$360K Buy
9,233
+1,724
+23% +$55.7K ﹤0.01% 1526
2026
Q1 		$244K Sell
7,509
-658
-8% -$21.1K ﹤0.01% 1593
2025
Q4 		$287K Buy
+8,167
New +$289K ﹤0.01% 1393

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vident Advisory's VKTX Position: Q2 2026 in Review

Vident Advisory increased its Viking Therapeutics (VKTX) stake by 23% in Q2 2026, buying an estimated $55.7K and bringing the position to 9,233 shares worth $360K. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

Vident Advisory first reported a position in VKTX in Q4 2025 and has held it in 3 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Vident Advisory held 9,233 shares of Viking Therapeutics worth $360K as of Q2 2026.
  • Vident Advisory bought 1,724 Viking Therapeutics shares in Q2 2026, an estimated $55.7K.
  • Viking Therapeutics made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1526 holding.
  • Vident Advisory first reported a position in Viking Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.